So after 14 years, burning through somewhere in the Billion dollar range and having your two most promising drugs approved you'd consider it a success to break even or maybe even be slightly profitable.
Wait to you see the options that management gets and cashes in if copaxone is ever approved, no matter if they'll ever get close to covering their costs.
Market Data 
Markets 
AI
